Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis
- If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
- Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
- Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis
- If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
- Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
- Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis
- If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
- Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
- Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
ADDRESS
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
CALL US
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
